Member Info for inanaco

Knowlesi ... so what happened to orphan status ? 7 year exclusive access

what happened to 5 year patent ext for Bio ....

do we need another rerun of the work arounds ... ?

i use useful predictions ... for instance how much stone to cover 20 m x 50m with 200mm of stone

answer 379 tons ...

at £17 a ton Delivered "new"

or can i find road plannings or a demolition site and buy the waste ?

No i am expanding the property side, its still booming in Devon ...

Scancell is a side show, which is why i never concerned my self with "going all in "

however i find the science fascinating ...

earlier you said that a Million invested should yield £35,000 .... that 3.5%

my properties yield is higher at 7.7% of value ....

looks like i picked a winner ...

ATB

Ruck ... i am just a simple investor

ATB ...

mathematical High Flyers like yourself who develop probability software algo's ... etc etc ... gave us 15p in 2017 and 10p in 2018

those numbers i can prove

ATB

development, regulatory and sales milestone payments of up to $250.0 million in the SARS-CoV-2 Licensed Field, and one-time manufacturing milestone payments of up to $200.0 million

just for Covid ................

Scancell £27m

Covidity Value .......... zero

the sp was at this level BEFORE covidity

you now have a direct comparison ...

why do you need me ...... that is a deal done chap

https://translate.bio/pipeline/

dam .... can we fit that into 3.9 pence ...

If Sanofi Pasteur chooses to exercise its option to extend the Collaboration Term for an additional year, Sanofi Pasteur has agreed to pay the Company an additional $75.0 million. The Agreement and the Amendment collectively provide that the Company is eligible to receive aggregate potential payments of up to $1,940.0 million upon the achievement of additional specified development, regulatory, manufacturing and commercialization milestones. In particular, the Company is entitled to receive development, regulatory and sales milestone payments of up to $148.0 million for each Licensed Field other than the SARS-CoV-2 Licensed Field, development, regulatory and sales milestone payments of up to $250.0 million in the SARS-CoV-2 Licensed Field, and one-time manufacturing milestone payments of up to $200.0 million

Vaccine company Values ....

That includes $450 million in milestones under the 2018 deal, along with $360 million for the Covid-19 work.
https://endpts.com/sanofi-bets-425m-cash-on-a-transformation-style-next-gen-vaccine-deal-as-the-big-pharma-team-makes-a-point/

well lets just stick to your £10 ... all good

happy with it

thanks

Not out to prove anything ........

i don't need to i have over 800,000 shares running on Scancell ...

i am not responsible for other peoples Money ........... only my own

ATB

My descriptions or Your's

Ruck holds any prediction as factual ..

so if you use ....... a £1 on the cards ........... that becomes fact with the brain dead ...

on the cards
phrase of card
possible or likely.

Scancell Holdings has appointed six world-leading clinicians to establish its Clinical Advisory Board (CAB). The Board will be chaired by Professor Robert Coleman and will provide strategic guidance and support. This will be especially needed as the cancer immunotherapy company prepares for its lead Moditope candidate, Modi-1, to enter the clinic in Q1 2020 in multiple tumour types, including head and neck, breast and ovarian cancer.

The CAB comprises:

Professor Robert Coleman, Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield
Professor Christian Ottensmeier, Professor of Experimental Cancer Medicine at the University of Southampton
Professor Poulam Patel, Professor of Clinical Oncology at the University of Nottingham and Honorary Consultant Medical Oncologist at the Nottingham University Hospitals NHS Trust
Professor Iain McNeish, Professor of Oncology and Head of the Division of Cancer within the Department of Surgery and Cancer, Imperial College London Professor David Miles, Lead Clinician for breast cancer at Mount Vernon Cancer Centre; and Professor Stephen Chan, Director of Clinical Trials in Breast Cancer and Gynaecological Cancer at Nottingham University Hospital

why would they do that ?

its only a phase 1 trial to start only, if we get "responses" will they proceed ... ........... what are they expecting ?

Replay to Sir Dick

Scancell receives “significant scientific endorsement” for technology
The company teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge

dickpullar

Posts: 733

Price: 5.70

No Opinion

RE: Thoughts23 Jun 2020 12:59
My handle is definitely your trait Inan..making out Roche will come in is absolute tosh and well you know it.

Ruck i would also remind you of this

""""" I’m not looking at my shares as cash in the bank, I appreciate that there may at times be a gap between the underlying value of a share and what it changes hands for on the stock exchange.
I know I’m in control as to the timing of an exchange back to cash.
I accept that once we have “great data” we are in a position to negotiate “great deals” """"

that you posted

I accept that once we have “great data” we are in a position to negotiate “great deals”

Job done eh ! .... "anticipation" ...........

I could easily ........ however one flaw in your request

You keep telling us the criteria ...

so why don't you do it .. !!

which stock market ?

I hope you are not reliant on AIM investors to give you some sort of value are you ?